Research programme: epigenetic targeted therapeutics - Ignyta

Drug Profile

Research programme: epigenetic targeted therapeutics - Ignyta

Alternative Names: Autoimmune disorder therapeutics - Ignyta; Cancer therapeutics - Ignyta; Immuno-oncology therapeutics - Ignyta; Spark-1; Spark-1 Rx/Dx Program; Spark-2; Spark-2 Rx/Dx Program; Spark-3; Spark-3 Rx/Dx Program

Latest Information Update: 10 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Actagene-Oncology; Ignyta
  • Developer Ignyta
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Oct 2014 Active development is ongoing in the US
  • 31 Oct 2013 Ignyta and Infinity Oil & Gas Company complete a reverse merger
  • 29 May 2013 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top